An effective antitumor response following combination therapy of kinase inhibitors and anti-PD-1 or anti-PD-L1 antibodies requires both the presence of CD8+ T cells in the tumor microenvironment (TME) and CD8+ T cell-tumor cell interactions. The gene discussed is CD8A; the disease is neoplasm.